Mitochondria-Targeted Iron Chelator Offers Photoprotection

This article originally appeared here.
Share this content:
Mitochondria-Targeted Iron Chelator Offers Photoprotection
Mitochondria-Targeted Iron Chelator Offers Photoprotection

FRIDAY, July 29, 2016 (HealthDay News) -- A mitochondria-targeted iron chelator can protect primary skin fibroblasts against the harmful effects of ultraviolet A (UVA), according to a study published in the August issue of the Journal of Investigative Dermatology.

Olivier Reelfs, Ph.D., from the University of Bath in the United Kingdom, and colleagues designed a mitochondria-targeted hexadentate iron chelator linked to mitochondria-homing SS-like peptides. They evaluated the photoprotective potential of this compound against UVA-induced oxidative damage and cell death in cultured primary skin fibroblasts.

The researchers found that the compound provided protection against UVA-induced mitochondrial damage, depletion of adenosine triphosphate, and the ensuing necrotic cell death. This effect was fully related to the iron-chelating property in the mitochondria.

"This mitochondria-targeted iron chelator has therefore promising potential for skin photoprotection against the deleterious effects of the UVA component of sunlight," the authors write.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

900 Steps Tied to Functional Decline in Hospitalized Seniors

<900 Steps Tied to Functional Decline in Hospitalized ...

Walking <900 steps/day linked to hospitalization-associated functional decline

Thromboprophylaxis Not Effective After Knee Arthroplasty, Casting

Thromboprophylaxis Not Effective After Knee Arthroplasty, Casting

Does not prevent venous thromboembolism after knee arthroplasty, casting of lower leg

ASH: Lower Rate of Sickle Cell Pain Crises With Crizanlizumab

ASH: Lower Rate of Sickle Cell Pain Crises ...

Lower rate of crises per year; longer median time to first, second crises with high-dose therapy

is free, fast, and customized just for you!

Already a member?

Sign In Now »